When do you utilize lenalidomide in patients with MDS without del(5q)?
Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?
1 Answer
Mednet MemberInvited Expert
Hematology · UMass Chan Medical School
Answered on
Lenalidomide is beneficial in low-risk and int -1 risk MDS patients with anemia even without del 5q in combination with EPO as shown in ECOG 2905 study.
These low-risk MDS tend to be MDS with refractory anemia and ringed sideroblasts.
MDS RS with thrombocytosis tends to be re...
Join for free or sign in to see the full answer